Acute poisoning in adults: toxidrome recognition and initial management

Clinical scope and immediate priorities

Most poisoned patients are saved by high-quality supportive care rather than an antidote. The first priorities are airway, ventilation, circulation, glucose, temperature and seizure control, while history, containers, prescriptions and toxidrome findings narrow the likely exposure. Emergency care prioritises physiology and immediate threats before definitive diagnosis. Reassessment is essential because response to treatment, evolving symptoms and serial observations often provide more information than the initial snapshot. Clear escalation, handover and safety-netting reduce risk when diagnostic uncertainty remains.

Recognition and differential diagnosis

Look for patterns such as opioid respiratory depression and miosis, sympathomimetic agitation and hyperthermia, anticholinergic delirium and dry skin, cholinergic secretions and bradycardia, or sedative-hypnotic coma. Mixed overdoses are common and can blur textbook patterns. Assess intent and safeguarding once the patient is medically stable. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Obtain ECG early because QRS or QT abnormalities can identify sodium-channel blockade or arrhythmic risk. Check glucose, electrolytes, acid-base status and targeted drug concentrations when they change management, such as paracetamol/acetaminophen. Broad indiscriminate toxicology screens often have limited clinical value. Consider pregnancy testing when relevant. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Support ventilation and circulation, treat seizures promptly and use specific antidotes when the syndrome and risk justify them. Activated charcoal is reserved for selected significant ingestions within an appropriate time and with a protected airway. Sodium bicarbonate, naloxone, N-acetylcysteine and other antidotes have specific indications; dosing should follow current toxicology guidance. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Severe cardiotoxicity, refractory seizures, hyperthermia, metabolic acidosis or organ failure warrants toxicology and critical-care input. Haemodialysis or extracorporeal therapy is useful for selected dialysable toxins, guided by concentration, clinical severity and expert recommendations. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. After medical stabilisation, address intentional self-harm risk, medication access and substance-use treatment where relevant. Ensure delayed-toxicity substances have an adequate observation and repeat-testing plan.

Common pitfalls and safety checks

Do not rely on a routine urine drug screen to rule out clinically important poisoning. Supportive airway and ventilation care often matters more than finding an antidote. Activated charcoal is not benign when aspiration risk is high. A normal initial examination does not exclude delayed toxicity from some agents. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Emergency implementation is built around repeat observation. Record response to initial treatment, not just the first vital signs, and ensure pending tests or unresolved diagnostic uncertainty are handed over explicitly. Procedures and medicines should follow local resuscitation policy while preserving the same physiological priorities. Before discharge, confirm that the patient can access follow-up and understands precise return precautions. Where specialist services are distant, early consultation and transfer planning should occur in parallel with stabilisation rather than after deterioration.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.